drugset
drugset / Trial / NCT02732119

Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.

NCT02732119 ↗

Phase 1/2 Completed 104 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is determine if the triplet combination of ribociclib, everolimus and exemastane is safe and effective in the treatment of locally advanced/metastatic breast cancer following treatment with a CDK 4/6 inhibitor

Timeline

Start
2016-06-14
Primary completion
2020-02-25
Completion
2020-02-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule 2.5 mg Oral
Subject Everolimus Small molecule 5 mg Oral
Subject Exemestane Small molecule 25 mg Oral
Subject Ribociclib Small molecule 200 mg Oral
Subject Ribociclib Small molecule 250 mg Oral
Subject Ribociclib Small molecule 300 mg Oral

Indications

breast cancer